Drug intelligence / Profile preview

HY-007

Development stage: Discontinued
Lead developer: Juventas Cell Therapy
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

HY-007 is a chimeric antigen receptor (CAR) T-cell therapy product that targets both CD123 (interleukin-3 receptor alpha-subunit) and CD33 antigens. It was developed for the treatment of hematological malignancies, particularly acute myeloid leukemia (AML). The dual targeting of CD123 and CD33 aims to enhance anti-leukemic efficacy by addressing tumor heterogeneity and reducing the risk of relapse due to antigen escape. The drug was initially developed by Juventas Cell Therapy.

Other names: HY 007HY007HY-007

Targets

CD33 (Myeloid cell surface antigen CD33)IL3RA (Interleukin 3 Receptor)

Beyond the preview

Go deeper on HY-007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HY-007.

Explore the full profile